The use of patient-reported outcome and experience measures for health policy purposes: A scoping review in oncology.

Healthcare organisations Healthcare quality indicators Patient-reported measures Patient-reported outcome measures, Patient-reported experience measures Performance assessment

Journal

Health policy (Amsterdam, Netherlands)
ISSN: 1872-6054
Titre abrégé: Health Policy
Pays: Ireland
ID NLM: 8409431

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 14 12 2021
revised: 12 12 2022
accepted: 19 12 2022
pubmed: 2 1 2023
medline: 15 2 2023
entrez: 1 1 2023
Statut: ppublish

Résumé

The systematic use of patient-reported measures (PRMs) [i.e., patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs)] is advocated as an effective way to improve care practices. However, whether PRMs can lead to the performance assessment of healthcare organisations (HCOs) through valid quality indicators (QIs) for national purposes (i.e., public reporting and paying for performance) is open to debate. This study undertakes a scoping review to examine the use of PRMs as QIs for health policy purposes and to identify the challenges faced in the emblematic case of oncology. According to PRISMA guidelines, published papers, websites and reports published by national and international initiatives were analysed using five online databases (Web of Science, Scopus, PubMed, JSTOR and Google Advanced Search), and then studied using the same keywords. We selected 61 articles and 19 websites/reports and identified 29 PREMs and 48 PROMs from 14 countries and two international initiatives that routinely used them as QIs for HCOs' comparisons. Four types of barriers to this specific use were identified relating to the definition of a standard set, scientific soundness, data collection, and the actionability of such measures. Despite current developments, different barriers still must be overcome before PRMs can be used for health policy purposes in oncology. Future research is needed to ensure that valid QIs related to PRMs are applied at a national level.

Identifiants

pubmed: 36588068
pii: S0168-8510(22)00316-5
doi: 10.1016/j.healthpol.2022.12.010
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

104702

Informations de copyright

Published by Elsevier B.V.

Auteurs

E Minvielle (E)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France; I3-CRG, Ecole polytechnique-CNRS, Institut Polytechnique de Paris, Palaiseau, France. Electronic address: etienne.minvielle@gustaveroussy.fr.

A Fierobe (A)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France; I3-CRG, Ecole polytechnique-CNRS, Institut Polytechnique de Paris, Palaiseau, France.

A Fourcade (A)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France.

M Ferrua (M)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France.

M di Palma (M)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France.

F Scotté (F)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France.

O Mir (O)

Gustave Roussy, Division of Interdisciplinary Patient Care Pathways (DIOPP), Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH